Patents by Inventor Amir Boufenzer

Amir Boufenzer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mesenchymal stem cells obtained from Wharton's jelly for the treatment of sepsis
    Patent number: 11963984
    Abstract: The disclosure relates to human mesenchymal stem cells from Wharton's jelly, a method for preparing them, and the therapeutic uses thereof, in particular for the treatment of sepsis and specifically septic shock. The treatment may involve the administration to a subject in need thereof a pharmaceutical composition including the human mesenchymal stem cells from Wharton's jelly and a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: April 23, 2024
    Assignees: UNIVERSITÉ DE LORRAINE, CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE NANCY
    Inventors: Danièle Bensoussan, Sébastien Gibot, Loïc Reppel, Caroline Laroye, Amir Boufenzer, Léonore Avercenc, Céline Huselstein
  • USE OF SOLUBLE TREM-1 LEVELS FOR IDENTIFYING SUBJECTS SUSCEPTIBLE TO RESPOND TO AN ANTI-INFLAMMATORY THERAPY
    Publication number: 20210364532
    Abstract: A method for identifying human subjects suffering from an inflammatory disorder susceptible to respond to a therapy, in particular to a TREM-1 inhibitor. In particular, an in vitro method for identifying a human subject suffering from an inflammatory disorder, preferably an acute inflammatory disorder such as SIRS, sepsis or septic shock, susceptible to respond to a therapy, in particular to a TREM-1 inhibitor. The method includes the steps of a) measuring the level of soluble triggering receptors expressed on myeloid cells-1 (sTREM-1) in a biological sample from the human subject, comparing the level of sTREM-1 measured at step a) to a predetermined sTREM-1 value, and c) identifying a human subject suffering from an inflammatory disorder with a level of sTREM-1 measured at step a) higher than the predetermined sTREM-1 value of step b) as susceptible to respond to a therapy, in particular to a TREM-1 inhibitor.
    Type: Application
    Filed: September 27, 2019
    Publication date: November 25, 2021
    Applicant: INOTREM
    Inventors: Marc DERIVE, Aurelie OLIVIER, Kevin CARRASCO, Martin KOCH, Margarita SALCEDO-MAGGUILLI, Amir BOUFENZER, Lucie JOLLY, Jean-Jacques GARAUD
  • Methods and kits for predicting the risk of having a cardiovascular disease or event
    Patent number: 10948498
    Abstract: A cardiovascular event or disease is prevented or treated in a subject by measuring the expression level of soluble Triggering Receptors Expressed on Myeloid cells-1 (sTREM-1) level in a sample from the subject and comparing it to a reference level. Based on this comparison, subjects that are at risk of having or developing a cardiovascular event or disease are identified, and administered a suitable therapy.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: March 16, 2021
    Assignees: INOTREM, APHP (Assistance Publique-Hôpitaux de Paris), INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Lorraine
    Inventors: Marc Derive, Sebastien Gibot, Hafid Ait-Oufella, Amir Boufenzer, Tabasomme Simon, Nicolas Danchin
  • MESENCHYMAL STEM CELLS OBTAINED FROM WHARTON'S JELLY FOR THE TREATMENT OF SEPSIS
    Publication number: 20200000856
    Abstract: The disclosure relates to human mesenchymal stem cells from Wharton's jelly, a method for preparing them, and the therapeutic uses thereof, in particular for the treatment of sepsis and specifically septic shock. The treatment may involve the administration to a subject in need thereof a pharmaceutical composition including the human mesenchymal stem cells from Wharton's jelly and a pharmaceutically acceptable excipient.
    Type: Application
    Filed: February 28, 2018
    Publication date: January 2, 2020
    Applicants: UNIVERSITÉ DE LORRAINE, CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE NANCY
    Inventors: Danièle BENSOUSSAN, Sébastien GIBOT, Loïc REPPEL, Caroline LAROYE, Amir BOUFENZER, Léonore AVERCENC, Céline HUSELSTEIN
  • Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (TREM-1) TREM-like transcript 1 (TLT-1) for treatment of cardiovascular diseases
    Patent number: 9657081
    Abstract: The present invention relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 2 and a function-conservative variant. The invention also relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 2 and a function-conservative variant for use in the treatment of a cardiovascular disease.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: May 23, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LORRAINE
    Inventors: Sebastien Gibot, Amir Boufenzer, Hafid Ait-Oufella, Marc Derive
  • METHODS AND KITS FOR PREDICTING THE RISK OF HAVING A CARDIOVASCULAR DISEASE OR EVENT
    Publication number: 20160187352
    Abstract: The present invention relates to a method for diagnosing a cardiovascular event or disease in a subject by measuring sTREM-1 level in a sample.
    Type: Application
    Filed: August 8, 2014
    Publication date: June 30, 2016
    Inventors: Marc DERIVE, Sebastien GIBOT, Hafid AIT-OUFELLA, Amir BOUFENZER, Tabasomme SIMON, Nicolas DANCHIN
  • INHIBITING PEPTIDES DERIVED FROM TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1) TREM-LIKE TRANSCRIPT 1 (TLT-1) AND USES THEREOF
    Publication number: 20150232531
    Abstract: The present invention relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 2 and a function-conservative variant. The invention also relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 2 and a function-conservative variant for use in the treatment of a cardiovascular disease.
    Type: Application
    Filed: September 9, 2013
    Publication date: August 20, 2015
    Inventors: Sebastien Gibot, Amir Boufenzer, Hafid Ait-Oufella, Marc Derive